You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Centre examining all possible storage facilities for Pfizer's Covid vaccine

The Union Health Ministry said that the central government is examining all possibilities to extend cold chain facilities in case Pfizer's Covid-19 vaccine needs to be procured

Topics
Coronavirus Vaccine | India | Pfizer

ANI  |  General News 

Vaccine
Representative photo of a vaccine

 

New Delhi [India], November 18 (ANI): The Union on Tuesday said that the central government is examining all possibilities to extend cold chain facilities in case Pfizer's COVID-19 vaccine needs to be procured.

Responding to a query on vaccine storage at low temperature, Dr VK Paul, NITI Aayog member (Health) said it would be a huge challenge for any country to maintain cold chain facility at a lower temperature of -70 degree or -80 degree celsius and scale-up vaccine procurement.

"However, knowing all the circumstances, we are examining how to scale up vaccine storage facilities."

"We are keeping a close watch on the development of these vaccines and we are also aware of the fact that we won't be able to get a large number of doses of this vaccine required for our population. In case, union government procures it, all necessary arrangements will be made parallelly," said Dr Paul at a media briefing on COVID-19 update in

The NITI Aayog member further said that there are five COVID-19 vaccine candidates under various stages of clinical trials in of which two are in the third phase.

"is one of the countries which is showing good progress in COVID-19 vaccine trials. Serum Oxford vaccine is in the completion of the phase 3 trials and Bharat Biotech's COVID-19 vaccine's candidate has begun phase 3 trials and the results for phase 2 trials can be announced any time. Zydus Cadila has completed phase 2 trials" Dr Paul said.

"The Russian vaccine in collaboration with Dr Reddy's Laboratories will begin phase 2 and 3 clinical trials soon while Biological E vaccine's early phase 1 and 2 clinical trials have been launched," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 18 2020. 00:15 IST
RECOMMENDED FOR YOU